Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 6;3(1):44.
doi: 10.1186/s42466-021-00140-1.

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Heinz Wiendl  1 , Ralf Gold  2 , Frauke Zipp  3 ; Multiple Sclerosis Therapy Consensus Group
Collaborators, Affiliations
Review

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Heinz Wiendl et al. Neurol Res Pract. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicting interests for all authors are listed in the supplementary file of this article.

Figures

Fig. 1
Fig. 1
Disease-Modifying Therapy of MS. 1 - Azathioprine is formally approved but rarely applied (2nd choice); 2 - Mitoxantrone formally approved here as well as in highly active RRMS but rarely applied due to the unfavorable side effect profile and the cumulative maximum dose (2nd choice); 3 - Natalizumab: both i.v. and s.c.; especially in case of HPyV-2 (JCV) antibody positivity (HPyV-2 [JCV] Ab ≥0.9 HPyV-2 [JCV] Ab titer) risk stratification is essential due to PML risk! High risk for PML after i) prior immunosuppression, ii) ≥ 18 months of continuous therapy, and with iii) positive HPyV-2 (JCV) Ab status; 4 - Interferons: interferon-b-1a i.m., interferon-b-1a s.c., interferon-b-1b s.c., pegylated interferon-b-1a s.c./i.m.; 5 - Glatiramer acetate includes other glatiramoids. 6 - Decisions on type of therapy (as well as therapy concept) depend on the level of disease activity and severity; thus first- and second-line therapies are included here. Available drugs are listed alphabetically, not by strength or preference. Scheme from: MSTCG, DGNeurology Kommentar (2021) 10.1007/s42451-021-00353-3
See this image and copyright information in PMC

References

    1. Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS, the Danish Multiple Sclerosis Group & Danish multiple sclerosis group Early versus later treatment start in multiple sclerosis: A register-based cohort study. Eur J Neurol. 2018;25(10):1262–e110. doi: 10.1111/ene.13692. - DOI - PubMed
    1. He A, Merkel B, Brown JWL, MSBase study group et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–316. doi: 10.1016/S1474-4422(20)30067-3. - DOI - PubMed
    1. Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, Beiki O, Glaser A, Hillert J. Importance of early treatment initiation in the clinical course of multiple sclerosis. Multiple Sclerosis. 2017;23(9):1233–1240. doi: 10.1177/1352458516675039. - DOI - PubMed
    1. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, for the MSBase Study Group & MSBase study group Association of Initial Disease-Modifying Therapy with Later Conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–187. doi: 10.1001/jama.2018.20588. - DOI - PMC - PubMed
    1. Gass A, Costello FE. Optic neuritis in the diagnosis of MS: More than meets the eye. Neurology. 2018;91(12):545–546. doi: 10.1212/WNL.0000000000006189. - DOI - PubMed

LinkOut - more resources